UNSPSC 51241122: Pegaptanib

This classification denotes an angiogenesis inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H1PA8H1EN. European Medicines Agency schedules Pegaptanib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25196. Pegaptanib generally arises in the molecular formula C15H28N3O6(C2H4O)N(C2H4O)N. The term PEGAPTANIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, no. 2, 2003, list 49.) Most nations schedule pegaptanib under HS 39072021 and SITC 57419.

As of Q4 2014, PEGAPTANIB remains the US FDA Preferred Term for this commodity. Pegaptanib bears US NLM identifiers UMLS ID C1531015 and NCI Concept Code C90657. SMILES: COCCOC(=O)NCCCCC(C(=O)NCCCCCCCOP(=O)(C)O)NC(=O)OCCOC.

UNSPSC 51241122 Pegaptanib is a Commodity code for a specific pharmaceutical product supplied through cooperative purchasing agreements to state and local government facilities. State and local governments procure pegaptanib and similar branded or generic pharmaceuticals through multistate cooperative purchasing vehicles that establish master agreements with manufacturers, wholesalers, and authorized distributors. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities, including Oregon. Issuing bodies under this code are primarily state purchasing offices and cooperative purchasing alliances that aggregate demand across multiple jurisdictions and member agencies. Individual state and local health systems, departments, and procurement offices then draw on these master agreements to source specific pharmaceutical products for clinical and operational use.

MMCAP's January 2026 RFP illustrates the scope and mechanics of activity under the code: manufacturers must certify cGMP compliance and Drug Supply Chain Security Act adherence, maintain contractual relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), submit detailed product data including NDC codes and packaging configurations, and accept pricing structures ranging from flat rates to WAC-minus formulas. Evaluation weighted price competitiveness at 75 percent, with administrative compliance, EDI capability, and contractual terms comprising the remainder. The contract term runs two years for new vendors, with optional extensions, and vendors must carry $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability coverage. Products must be available by May 15, 2026, with awards effective July 1, 2026, and proposals were due March 26, 2026. The RFP does not disclose specific budget ranges or dollar values and reserves award authority for sole, dual, or multi-awards based on therapeutic and patient-safety considerations. No geographic concentration or standout repeat buyers beyond MMCAP itself appear in the recent opportunities block.